SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid beta (Abeta), with a dissociation constant (KD) of 0.43 nM for fibrillar Abeta, which is higher than for monomeric Abeta. It significantly hinders brain amyloid plaque formation, oligomer-induced synaptic dysfunction, and neuronal loss. Furthermore, SAR228810 offers substantial protection against Abeta-mediated neurotoxicity. MINT1526A is applicable in Alzheimers disease imaging and immunotherapy research.
Target:
Beta Amyloid
* VAT and and shipping costs not included. Errors and price changes excepted
